Strict blood pressure control associates with decreased mortality risk by APOL1 genotype

Kidney International

Volumn 91, Issue 2, 2017, Pages 443-450

  Ku, Elaine ^a   Lipkowitz, Michael S ^b   Appel, Lawrence J ^c   Parsa, Afshin ^d,e   Gassman, Jennifer ^f   Glidden, David V ^a   Smogorzewski, Miroslaw ^g   Hsu, Chi yuan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e BALTIMORE VA MEDICAL CENTER   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

APOL1 genotype; CKD; mortality

Indexed keywords

AMLODIPINE; METOPROLOL; RAMIPRIL; ANTIHYPERTENSIVE AGENT; APOL1 PROTEIN, HUMAN; APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN;

ADULT; AFRICAN AMERICAN; APOL1 GENE; ARTICLE; BLACK PERSON; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ELEVATED BLOOD PRESSURE; FEMALE; FOLLOW UP; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; MORTALITY RISK; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; ARTERIAL PRESSURE; DRUG EFFECTS; GENETICS; HYPERTENSION; KIDNEY; MORTALITY; PATHOPHYSIOLOGY; PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; APOLIPOPROTEINS; ARTERIAL PRESSURE; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PROTECTIVE FACTORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85008412694     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.09.033     Document Type: Article

References (46)

1. Cowie, C.C., Port, F.K., Wolfe, R.A., et al. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 321 (1989), 1074–1079.
2. McClellan, W., Tuttle, E., Issa, A., Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis 12 (1988), 285–290.
3. Hall, Y.N., Hsu, C.Y., Iribarren, C., et al. The conundrum of increased burden of end-stage renal disease in Asians. Kidney Int 68 (2005), 2310–2316.
4. Hsu, C.Y., Lin, F., Vittinghoff, E., et al. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 14 (2003), 2902–2907.
5. Genovese, G., Friedman, D.J., Ross, M.D., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329 (2010), 841–845.
6. Lipkowitz, M.S., Freedman, B.I., Langefeld, C.D., et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 83 (2013), 114–120.
7. Parsa, A., Kao, W.H., Xie, D., et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 369 (2013), 2183–2196.
8. Quaggin, S.E., George, A.L. Jr., Apolipoprotein l1 and the genetic basis for racial disparity in chronic kidney disease. J Am Soc Nephrol 22 (2011), 1955–1958.
9. Tzur, S., Rosset, S., Skorecki, K., et al. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. Nephrol Dial Transplant 27 (2012), 1498–1505.
10. Tzur, S., Rosset, S., Shemer, R., et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128 (2010), 345–350.
11. Foster, M.C., Coresh, J., Fornage, M., et al. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 24 (2013), 1484–1491.
12. Hoy, W.E., Hughson, M.D., Kopp, J.B., et al. APOL1 risk alleles are associated with exaggerated age-related changes in glomerular number and volume in African-American adults: an autopsy study. J Am Soc Nephrol 26 (2015), 3179–3189.
13. Vanhollebeke, B., Truc, P., Poelvoorde, P., et al. Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I. N Engl J Med 355 (2006), 2752–2756.
14. Kasembeli, A.N., Duarte, R., Ramsay, M., et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. J Am Soc Nephrol 26 (2015), 2882–2890.
15. Atta, M.G., Estrella, M.M., Skorecki, K.L., et al. Association of APOL1 genotype with renal histology among black HIV-positive patients undergoing kidney biopsy. Clin J Am Soc Nephrol 11 (2016), 262–270.
16. Freedman, B.I., Langefeld, C.D., Andringa, K.K., et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 66 (2014), 390–396.
17. Larsen, C.P., Freedman, B.I., Apolipoprotein L1-associated nephropathy and the future of renal diagnostics. J Am Soc Nephrol 26 (2015), 1232–1235.
18. Madhavan, S.M., O'Toole, J.F., Konieczkowski, M., et al. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 22 (2011), 2119–2128.
19. Duchateau, P.N., Pullinger, C.R., Orellana, R.E., et al. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem 272 (1997), 25576–25582.
20. Ito, K., Bick, A.G., Flannick, J., et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res 114 (2014), 845–850.
21. Mukamal, K.J., Tremaglio, J., Friedman, D.J., et al. APOL1 genotype, kidney and cardiovascular disease, and death in older adults. Arterioscler Thromb Vasc Biol 36 (2016), 398–403.
22. Freedman, B.I., Langefeld, C.D., Lu, L., et al. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int 87 (2015), 176–181.
23. Ma, L., Langefeld, C.D., Comeau, M.E., et al. APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease. Kidney Int 90 (2016), 389–395.
24. Langefeld, C.D., Divers, J., Pajewski, N.M., et al. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int 87 (2015), 169–175.
25. Ku E, Gassman J, Appel L, et al. Blood pressure control and long-term risk of ESRD and mortality [e-pub ahead of print]. J Am Soc Nephrol. pii: ASN.2016030326. Accessed 11 August 2016.
26. Pogue, V., Rahman, M., Lipkowitz, M., et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension 53 (2009), 20–27.
27. DCCT/EDIC Research Group, de Boer, I.H., Sun, W., Cleary, P.A., et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365 (2011), 2366–2376.
28. Nathan, D.M., Cleary, P.A., Backlund, J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005), 2643–2653.
29. Wong, M.G., Perkovic, V., Chalmers, J., et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39 (2016), 694–700.
30. Agodoa, L.Y., Appel, L., Bakris, G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285 (2001), 2719–2728.
31. Gassman, J.J., Greene, T., Wright, J.T. Jr., et al. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 14 (2003), S154–S165.
32. Wright, J.T. Jr., Bakris, G., Greene, T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288 (2002), 2421–2431.
33. Appel, L.J., Middleton, J., Miller, E.R. 3rd, et al. The rationale and design of the AASK cohort study. J Am Soc Nephrol 14 (2003), S166–S172.
34. Appel, L.J., Wright, J.T. Jr., Greene, T., et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363 (2010), 918–929.
35. Sika, M., Lewis, J., Douglas, J., et al. Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study. Am J Kidney Dis 50 (2007), 78–89 89.e71.
36. Chobanian, A.V., Bakris, G.L., Black, H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003), 2560–2572.
37. How good are the data? USRDS data validation special study. Am J Kidney Dis 20 (1992), 68–83.
38. Fillenbaum, G.G., Burchett, B.M., Blazer, D.G., Identifying a national death index match. Am J Epidemiol 170 (2009), 515–518.
39. O'Hare, A.M., Rodriguez, R.A., Hailpern, S.M., et al. Regional variation in health care intensity and treatment practices for end-stage renal disease in older adults. JAMA 304 (2010), 180–186.
40. Sarnak, M.J., Greene, T., Wang, X., et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142 (2005), 342–351.
41. Quinn, J., Kramer, N., McDermott, D., Validation of the Social Security Death Index (SSDI): An Important Readily-Available Outcomes Database for Researchers. West J Emerg Med 9 (2008), 6–8.
42. Ku, E., Glidden, D.V., Johansen, K.L., et al. Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. Kidney Int 87 (2015), 1055–1060.
43. Chen, T.K., Choi, M.J., Kao, W.H., et al. Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression. Clin J Am Soc Nephrol 10 (2015), 2128–2135.
44. Alves, T.P., Wang, X., Wright, J.T. Jr., et al. Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. J Am Soc Nephrol 21 (2010), 1361–1369.
45. Norris, K., Bourgoigne, J., Gassman, J., et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis 48 (2006), 739–751.
46. Gabbai, F.B., Rahman, M., Hu, B., et al. Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKD. Clin J Am Soc Nephrol 7 (2012), 1770–1776.